Supplemental material
Journal of Medical Economics
Volume 24, 2021 - Issue 1
Hematology
Cost analysis of the impact of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura from a US hospital perspective
, , 
&
Marie Fourniera Sanofi, France, Chilly-Mazarin, Paris, Francehttps://orcid.org/0000-0002-3805-1706
https://orcid.org/0000-0002-3805-1706 & Huy P. Phamc National Marrow Donor Program, Seattle, WA, USA;d Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USAhttps://orcid.org/0000-0003-4168-3859
https://orcid.org/0000-0003-4168-3859Related Research Data
Cost analysis of the impact of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura from a US hospital perspective
Source:
Taylor & Francis
Linking provided by
